Blood–brain barrier

Vect-Horus Strengthens its Scientific Advisory Board with the Appointment of Pr. Xavier Declèves

Retrieved on: 
Thursday, January 11, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Faculty, Toxicology, Pharmacy, BBB, Head, SAB, Pharmacokinetics, Blood–brain barrier, CNS

Xavier Declèves to its scientific advisory board (SAB).

Key Points: 
  • Xavier Declèves to its scientific advisory board (SAB).
  • Jean-Manuel Péan, Chief Scientific Officer of Vect-Horus commented, “We are pleased to welcome Xavier in our SAB.
  • Declèves, our SAB now has a tremendous level of scientific expertise that will be instrumental in advancing our technology and programs.
  • “ I'm delighted to join the Vect-Horus Advisory Board and share my expertise and ideas around targeting technologies dedicated to modern therapeutic modalities ” commented Xavier Declèves.

Fasano Longevity Conference Covers Politics, Investments, and Medical Research

Retrieved on: 
Thursday, November 9, 2023
Consulting, Other Professional Services, Professional Services, Insurance, Research, Life expectancy, Northwestern Memorial Hospital, Ultrasound, Blood–brain barrier, Next, Conference, Longevity, Senescence, Use

Two hundred longevity professionals attended the 20th Annual Fasano Longevity Conference in Washington, DC.

Key Points: 
  • Two hundred longevity professionals attended the 20th Annual Fasano Longevity Conference in Washington, DC.
  • The conference, which was in hybrid format, with about 170 attending in person and 30 attending virtually, focused on a wide range of topics bearing on longevity markets, medical research, and the primary elections.
  • It covered a very interesting mix of topics bearing on longevity markets and some very cutting-edge research.” Fasano described the Conference as investor focused.
  • Next year’s Fasano Longevity Conference will be held on Monday, November 4th in Washington, DC.

Kyowa Hakko's Cognizin® Featured in 16 New Re-Formulations in RYSE Supplements!

Retrieved on: 
Wednesday, December 6, 2023
Attention, Research, Blood–brain barrier, Stock, Kyowa Kirin, Memory, The Signature Series, Dietary supplement

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- RYSE Supplements, in collaboration with Kyowa Hakko, has announced the launch of 16 newly reformulated SKUs featuring the premium ingredient Cognizin® Citicoline. Cognizin® from Kyowa Hakko is a clinically tested form of citicoline known for its effects due to its ability to cross the Blood Brain Barrier. This innovative ingredient supports brain energy, focus, attention, and memory.

Key Points: 
  • The Next Level Brain Power: Kyowa Hakko's Cognizin® in 16 New RYSE Supplements Formulations!
  • NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- RYSE Supplements, in collaboration with Kyowa Hakko, has announced the launch of 16 newly reformulated SKUs featuring the premium ingredient Cognizin® Citicoline.
  • RYSE Loaded Pre introduces 8 delicious flavors, RYSE Godzilla Pre-Workout boasts 5 exciting options, and RYSE Stim Daddy brings 3 intense flavors to the lineup.
  • Additionally, RYSE VitaFocus and BCAA Focus, each available in 3 flavors, further expand the range to a total of 19 RYSE SKUs featuring Cognizin®.

Cordance Medical's NeuroAccess Receives FDA Breakthrough Device Designation for Liquid Biopsy in Brain Tumors

Retrieved on: 
Thursday, October 26, 2023
Neoplasm, FDA, GBM, Ageing, Food, Washington University in St. Louis, Nucleic acid thermodynamics, Parkinson's disease, Breakthrough, Microbubble, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Glioblastoma, Myenteric plexus, BBB, Blood–brain barrier, DSM-IV codes, Brain, System, Liquid biopsy, Alzheimer's disease, Patient, Diagnosis, DNA, Medical device, Medical imaging, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Oct. 26, 2023 /PRNewswire/ -- Cordance Medical, a pioneering medical device company focused on opening the Blood-Brain Barrier (BBB) to facilitate liquid biopsy, announces that its NeuroAccess™ device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 26, 2023 /PRNewswire/ -- Cordance Medical, a pioneering medical device company focused on opening the Blood-Brain Barrier (BBB) to facilitate liquid biopsy, announces that its NeuroAccess™ device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).
  • The FDA's Breakthrough Device Designation is conferred upon technologies that offer superior treatment or diagnosis for life-threatening or debilitating conditions.
  • "This Breakthrough Device Designation from the FDA is a pivotal milestone for Cordance Medical and for patients requiring more efficacious diagnostic solutions," said Ryan Dittamore, CEO of Cordance Medical.
  • "The Breakthrough Device Designation demonstrates Cordance Medical's commitment to design a safe, patient-centric device for patients with brain diseases," added Dr. Ramamurthy, CTO and co-founder of Cordance Medical.

Fasano Longevity Conference to Cover Politics, Investments and Medical Research

Retrieved on: 
Tuesday, October 24, 2023
Insurance, Finance, General Health, Health, Consulting, Professional Services, Health Insurance, Other Health, Local Investing Opportunity Network, Life expectancy, Longevity, MAAA, Fasano, Science, Originality, Uncertainty, Conference, Hart, Northwestern Memorial Hospital, Research, Ultrasound, Brain, Obesity, Actuarial science, Politics, Blood–brain barrier, ASA, Mortality, Harte Research Institute for Gulf of Mexico Studies, LARA, Risk management, Life insurance, Ageing

The Fasano Longevity Conference , which will be held on November 6th in Washington, DC, will explore a broad range of subjects and feature industry experts to discuss relevant topics bearing on longevity markets.

Key Points: 
  • The Fasano Longevity Conference , which will be held on November 6th in Washington, DC, will explore a broad range of subjects and feature industry experts to discuss relevant topics bearing on longevity markets.
  • Will Ketterer , Obra Capital, Longevity CIO: The Impact of Interest Rates on Structured Settlements and Other Longevity Sensitive Assets.
  • Rahul Nawander , Fasano Associates Medical Director: An analysis on the Relationship Between Obesity and Increased Mortality
    Said Michael Fasano, "This year's conference has something for everyone - from politics to breakthrough medical research."
  • With a registration fee of only $595 and eight original presentations, Fasano characterized his conference as "the best value in the business."

INSIGHTEC NAMED BIOFLORIDA COMPANY OF THE YEAR

Retrieved on: 
Monday, October 16, 2023
Partnership, Permeability, Conference, Essential tremor, Movement disorder, Bioceramic, Health, RTI, The Advisory Board Company, FDA, Insightec, OPKO Health, Growth, Ology, Tremor, Blood–brain barrier, NEXT Woman of the Year awards, Research, Catalyst Pharmaceuticals, MRI, Axogen, Parkinson's disease, Liquid biopsy, Prostate, Brain, FUS, Patient, Quality of life, Medical imaging, Pharmaceutical industry

MIAMI, Oct. 16, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida's life sciences industry. The award was presented at BioFlorida's 26th Annual Conference in Ponte Verdra Beach to an audience of statewide leaders in Florida's life sciences industry.

Key Points: 
  • MIAMI, Oct. 16, 2023 /PRNewswire/ -- Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida's life sciences industry.
  • The David J. Gury Company of the Year Award, named for one of the founding directors of BioFlorida, honors a company that has significant company achievements with measurable results including financing deals, partnering agreements, research discoveries, grants, clinical trials, approvals, product development and commercialization milestones.
  • Recipients must also be BioFlorida members who demonstrate a history of service to BioFlorida and its mission - to advance the life sciences industry in Florida.
  • Insightec is also exploring other treatment applications in the body, such as prostate disease.

Realeve Unveils Breakthrough Solution to Treat Central Nervous System Disorders Including Stroke and Cluster Headache; Bypasses Brain’s Natural Barrier to Deliver Therapeutics

Retrieved on: 
Thursday, September 21, 2023
Research, Other Health, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Science, Neurology, Biotechnology, FDA, Health, Other Science, Cleveland Clinic, Central nervous system, Alzheimer's disease, Neoplasm, HA, Stroke, CE marking, Post-stroke depression, Case Western Reserve University, Multimedia, Cluster headache, Brain damage, Brain, CNS, DSM-IV codes, SPG, System, BBB, Patient, Myenteric plexus, Autonomic nervous system, Blood–brain barrier, Cleveland, Pulsant, Medical device, Dentistry, Dermatology

Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.

Key Points: 
  • Realeve has also been granted Breakthrough Device designation from the FDA with a goal of obtaining FDA approval and CE Mark to treat cluster headaches in 2024.
  • We are also exploring its applications in other central nervous system disease conditions and excited about the potential,” states Dr. Peter Bonutti, founder and president, Realeve.
  • This technology holds promise for addressing conditions like Alzheimer's, tumors, and other central nervous system disorders.
  • The targeted therapy provides both pain relief, and can increase blood flow and medication delivery to the central nervous system.

6th Annual Neuroscience R&D Conference, London, United Kingdom - October 9-10, 2023

Retrieved on: 
Thursday, September 21, 2023
Interactivity, University, Therapy, Senior, Blood–brain barrier, Proteomics, CNS, Assistant, University of Nottingham, Patient, Access, University of Sheffield, Drug discovery, Neurology, AI, Conference, Alzheimer's disease, University of Oxford, Medical device, Pharmaceutical industry, Neuroscience, Translational neuroscience

DUBLIN, Sept. 21, 2023 /PRNewswire/ -- The "Neuroscience R&D Conference" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 21, 2023 /PRNewswire/ -- The "Neuroscience R&D Conference" conference has been added to ResearchAndMarkets.com's offering.
  • With the advent of neural implants and novel therapies, the cure of multiple neurodegenerative disorders proves wholesome for the patients' suffering.
  • The increasing in severity of neurodegenerative diseases, demands the discovery of new translational approaches in neuroscience research.
  • Case studies presented from leading technology collaborations, Interactive panels, and breakout sessions along with Access to online presentations on-demand post-summit.

Neuroscience R&D Conference 2023: Unfolding the Recent Advancements in Preclinical and Translational Approaches Treating Neurodegenerative Disorders (London, United Kingdom - October 9-10, 2023) - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 29, 2023
Science, Health, Neurology, Research, Knowledge, Interactivity, Therapy, Blood–brain barrier, Proteomics, CNS, Patient, Access, Drug discovery, AI, Conference, Participation, Pharmaceutical industry, Marketing, Medical device

Unfolding the recent advancements in preclinical and translational approaches treating neurodegenerative disorders.

Key Points: 
  • Unfolding the recent advancements in preclinical and translational approaches treating neurodegenerative disorders.
  • With the advent of neural implants and novel therapies, the cure of multiple neurodegenerative disorders proves wholesome for the patients' suffering.
  • The increasing in severity of neurodegenerative diseases, demands the discovery of new translational approaches in neuroscience research.
  • The conference will be centered on focusing on the most recent advancements in preclinical, translational neuroscience research while also bringing the audience's attention to the emerging role of AI and big data in the neuroscience R&D space.

FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit

Retrieved on: 
Thursday, June 1, 2023
Astrocyte, Drug development, Central nervous system, Medium (website), IPSC, Pericyte, Stroke, 3D, Blood–brain barrier, DSM-IV codes, Pharmacokinetics, Hope, Physiology, Traffic barrier, Brain, Research, Cell, CNS, Neuroscience, Dementia, Animal, ICEL Psalter, Permeability, Patient, Drug discovery, Microglia, Neurological disorder, Migraine, WHO, IPS, Meningitis, World Health Organization, Medical imaging

The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.

Key Points: 
  • The first-of-its-kind kit models the human blood-brain barrier and can advance drug discovery, drug development and medical research for central nervous system (CNS) disorders.
  • The iCell Blood-Brain Barrier Isogenic Kit is an off-the-shelf, ready to use, human iPSC-derived cell model that has barrier integrity and functionality consistent with in vivo physiological properties.
  • The iCell Blood-Brain Barrier Isogenic Kit is commercially available and will begin shipping by the end of June 2023.
  • To learn more about FUJIFILM Cellular Dynamics’ blood-brain barrier cellular model, you can visit https://www.fujifilmcdi.com/icell-blood-brain-barrier-kit-coming-soon/ .